{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T16:27:48Z","timestamp":1780936068255,"version":"3.54.1"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To compare the adverse event rates between daptomycin and vancomycin in the outpatient parenteral antimicrobial therapy (OPAT) setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective cohort study of patients treated with vancomycin or daptomycin in OPAT. Demographic and clinical data were abstracted from the electronic medical record. Vancomycin was dosed using Bayesian kinetics software to achieve a goal AUC of 400\u2013600\u2005mg h\/L and daptomycin was a weight-based dose. The primary outcome was the occurrence of an adverse event resulting in a change in antimicrobial therapy or early discontinuation due to harm or injury. Secondary outcomes included measurement of time to adverse event occurrence and time in therapeutic range for the vancomycin group. The primary outcome was analyzed using a chi-square test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 175 patients were included, with 112 in the daptomycin group and 63 in the vancomycin group. The primary outcome of early discontinuation of OPAT therapy was not statistically different between the daptomycin and vancomycin groups [15\/112 (13%) versus 9\/63 (14%); P\u200a=\u200a0.87]. The daptomycin group demonstrated a shorter median time to adverse event occurrence compared with the vancomycin group (12 versus 30\u2005days).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>When comparing the rate of early discontinuation between daptomycin and vancomycin in OPAT, there was no significant difference between groups. These findings suggest that either agent may be considered in the OPAT setting depending on patient-specific factors. Dosing of vancomycin using Bayesian model dosing software may have led to a reduction of adverse events in the vancomycin group.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jacamr\/dlaf227","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:57:08Z","timestamp":1763038628000},"source":"Crossref","is-referenced-by-count":1,"title":["Adverse events leading to discontinuation of daptomycin versus vancomycin in outpatient parenteral antimicrobial therapy: a retrospective cohort study"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2336-6816","authenticated-orcid":false,"given":"Kristin","family":"Lanier","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, FirstHealth of the Carolinas , 155 Memorial Dr, Pinehurst, NC 28374 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaspaul","family":"Jawanda","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, FirstHealth of the Carolinas , 155 Memorial Dr, Pinehurst, NC 28374 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5602-1677","authenticated-orcid":false,"given":"Allison","family":"Cid","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, FirstHealth of the Carolinas , 155 Memorial Dr, Pinehurst, NC 28374 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"2025112807325912700_dlaf227-B1","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciy867","article-title":"2018 Infectious Diseases Society of America Clinical Practice Guideline for the management of outpatient parenteral antimicrobial therapy","volume":"68","author":"Norris","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2025112807325912700_dlaf227-B2","author":"Pharmacy Times"},{"key":"2025112807325912700_dlaf227-B3","doi-asserted-by":"publisher","first-page":"ofae217","DOI":"10.1093\/ofid\/ofae217","article-title":"Counting the cost of daptomycin versus vancomycin in hospitalized patients: a cost minimization analysis","volume":"11","author":"Wagner","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2025112807325912700_dlaf227-B4","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists","volume":"77","author":"Rybak","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"2025112807325912700_dlaf227-B5","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/phar.2670","article-title":"Comparison of Bayesian-derived and first-order analytic equations for calculation of vancomycin area under the curve","volume":"42","author":"Olney","year":"2022","journal-title":"Pharmacotherapy"},{"key":"2025112807325912700_dlaf227-B6","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.addr.2014.05.016","article-title":"Innovative approaches to optimizing the delivery of vancomycin in individual patients","volume":"77","author":"Pai","year":"2014","journal-title":"Adv Drug Delivery Rev"},{"key":"2025112807325912700_dlaf227-B7","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1093\/jac\/dkt512","article-title":"Adverse events, healthcare interventions and healthcare utilization during home infusion therapy with daptomycin and vancomycin: a propensity score-matched cohort study","volume":"69","author":"Shrestha","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2025112807325912700_dlaf227-B8","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1017\/ice.2018.107","article-title":"A retrospective analysis of adverse events among patients receiving daptomycin versus vancomycin during outpatient parenteral antimicrobial therapy","volume":"39","author":"Schrank","year":"2018","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2025112807325912700_dlaf227-B9","doi-asserted-by":"publisher","first-page":"6213","DOI":"10.1128\/AAC.01563-13","article-title":"High-dose daptomycin therapy for left-sided infective endocarditis: a prospective study from the international collaboration on endocarditis","volume":"57","author":"Carugati","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2025112807325912700_dlaf227-B10","doi-asserted-by":"publisher","first-page":"ofae438","DOI":"10.1093\/ofid\/ofae438","article-title":"Put the Vanc Down, Flip It and Reverse It: comparison of vancomycin and daptomycin health care utilization and cost in outpatient parenteral antimicrobial therapy","volume":"11","author":"Streifel","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2025112807325912700_dlaf227-B11","doi-asserted-by":"publisher","first-page":"ofae600","DOI":"10.1093\/ofid\/ofae600","article-title":"Implementation of a pharmacist-driven vancomycin area under the concentration-time curve monitoring program using Bayesian modeling in outpatient parenteral antimicrobial therapy","volume":"11","author":"Gillett","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2025112807325912700_dlaf227-B12","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.japh.2021.11.031","article-title":"Outpatient vancomycin therapy: acute kidney injury in individualized AUC-based goal trough ranges versus traditional trough dosing","volume":"62","author":"Rees","year":"2022","journal-title":"J Am Pharm Assoc"},{"key":"2025112807325912700_dlaf227-B13","doi-asserted-by":"publisher","first-page":"C179","DOI":"10.1159\/000339789","article-title":"KDIGO clinical practice guidelines for acute kidney injury","volume":"120","author":"Khwaja","year":"2012","journal-title":"Nephron Clin Pract"},{"key":"2025112807325912700_dlaf227-B14","author":"FDA"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/7\/6\/dlaf227\/65608614\/dlaf227.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/7\/6\/dlaf227\/65608614\/dlaf227.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T12:33:01Z","timestamp":1764333181000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlaf227\/8350450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,10,30]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlaf227","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,10,30]]},"article-number":"dlaf227"}}